Johnson & Johnson (NYSE:JNJ) Shares Bought by Fullcircle Wealth LLC

Fullcircle Wealth LLC lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 21.9% during the 4th quarter, Holdings Channel reports. The firm owned 12,131 shares of the company’s stock after buying an additional 2,177 shares during the period. Fullcircle Wealth LLC’s holdings in Johnson & Johnson were worth $1,908,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. IFS Advisors LLC boosted its position in Johnson & Johnson by 138.9% in the 4th quarter. IFS Advisors LLC now owns 172 shares of the company’s stock valued at $25,000 after buying an additional 100 shares during the period. WealthTrak Capital Management LLC purchased a new position in Johnson & Johnson in the fourth quarter valued at $26,000. Mountain Hill Investment Partners Corp. acquired a new position in Johnson & Johnson during the 4th quarter worth $29,000. Bay Harbor Wealth Management LLC acquired a new stake in Johnson & Johnson in the 4th quarter valued at about $32,000. Finally, Conquis Financial LLC purchased a new position in shares of Johnson & Johnson in the 4th quarter valued at about $33,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the stock. Benchmark raised shares of Johnson & Johnson to a “strong-buy” rating in a report on Thursday, April 24th. The Goldman Sachs Group raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $157.00 to $172.00 in a research report on Wednesday, April 9th. Guggenheim reissued a “neutral” rating on shares of Johnson & Johnson in a report on Wednesday, April 2nd. Argus raised Johnson & Johnson to a “strong-buy” rating in a research report on Friday, January 24th. Finally, Stifel Nicolaus cut their target price on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a research report on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have issued a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus price target of $171.82.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $157.23 on Thursday. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $378.31 billion, a PE ratio of 23.64, a price-to-earnings-growth ratio of 2.56 and a beta of 0.42. The stock’s 50-day moving average price is $158.35 and its 200 day moving average price is $154.49. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.59 by $0.18. The business had revenue of $21.89 billion during the quarter, compared to analysts’ expectations of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. As a group, equities research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be issued a $1.30 dividend. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.24. The ex-dividend date of this dividend is Tuesday, May 27th. This represents a $5.20 annualized dividend and a yield of 3.31%. Johnson & Johnson’s dividend payout ratio is 57.84%.

Insiders Place Their Bets

In related news, VP Robert J. Decker sold 6,999 shares of the company’s stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the transaction, the vice president now directly owns 21,001 shares in the company, valued at approximately $3,483,645.88. This represents a 25.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Timothy Schmid sold 403 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares in the company, valued at approximately $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by company insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.